Controlled clinical trials最新文献

{"title":"Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year","authors":"Andrew J Vickers D.Phil. ,&nbsp;Rob McCarney M.Phil.","doi":"10.1016/j.cct.2003.10.001","DOIUrl":"10.1016/j.cct.2003.10.001","url":null,"abstract":"<div><p><span>We conducted a randomized controlled trial (ISRCTN96537534) to assess the effects of acupuncture on migraine and chronic tension headache. Patients (n</span> <!-->=<!--> <!-->401) completed a diary of headache severity four times a day for 4 weeks at baseline, immediately following a 3-month treatment period and 1 year after randomization. During the trial, it appeared that dropout might be higher than expected. We therefore obtained a rapid global assessment of headache from participants to aid imputation of missing data. Patients were contacted by telephone and asked to rate current and baseline headache on a 0–10 scale. Use of global assessment reduced the number of patients from whom we obtained no follow-up headache data from 69 (17%) to 24 (6%). Analysis of patients who provided both a diary and a global assessment demonstrated excellent properties of global assessment, with very similar results to the full diary. We therefore used the global assessment to help impute missing 1-year diary scores. Rapid global assessment can be easily implemented in any trial and aids imputation of missing data, though it should not be used instead of more intensive methods of assessment. Further research might usefully examine the value of global assessment for imputation of missing data in a variety of different settings.</p></div>","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages 731-735"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cct.2003.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24113706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics","authors":"Michiel L Bots M.D., Ph.D. ,&nbsp;Gregory W Evans M.A. ,&nbsp;Ward Riley Ph.D. ,&nbsp;Rudy Meijer M.Sc. ,&nbsp;Karen H McBride Ph.D. ,&nbsp;Electra D Paskett Ph.D. ,&nbsp;Frans A Helmond Ph.D. ,&nbsp;Diederick E Grobbee M.D., Ph.D. ,&nbsp;for the OPAL Investigators","doi":"10.1016/S0197-2456(03)00096-5","DOIUrl":"10.1016/S0197-2456(03)00096-5","url":null,"abstract":"<div><p>The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) trial is a three-arm, randomized, placebo-controlled, double-blind study to determine the effect of tibolone 2.5 mg (Org OD 14) and continuous combined conjugated equine estrogens plus medroxyprogesterone acetate (0.625 mg/2.5 mg respectively) on progression of intima-media thickness of the carotid arteries and bone mineral density of the lumbar vertebrae and proximal femur in postmenopausal women. A total of 866 healthy postmenopausal women were recruited in six U.S. centers and five European centers. Duplicate carotid ultrasound examinations of the common carotid artery, the carotid bifurcation, and the internal carotid artery were performed at baseline. Single measurements of bone mineral density of the lumbar vertebrae and proximal femur were obtained at baseline. After randomization, ultrasound examinations were repeated every 6 months for 36 months following baseline, with a duplicate examination at the end of the study. Bone mineral density was measured every 12 months throughout the trial. The primary outcome is change in mean common carotid intima-media thickness (CIMT), defined as the average of the intima-media thickness measurements performed circumferentially at predefined angles for the near and far wall of 10-mm segments of the right and left distal common carotid arteries. Unique new features of the OPAL study are the specifically developed OPAL ultrasound protocol, yielding highly reproducible CIMT measurements, and the use of two experienced core laboratories for CIMT readings (one in the United States and one in Europe) with one common quality assurance and control program. The OPAL study is a large, placebo-controlled trial evaluating the effects of tibolone, as well as one of the first large randomized studies to determine the effects of continuous combined estrogen-progestin therapy on carotid atherosclerosis in healthy postmenopausal women. The OPAL study results are expected to complement other studies on atherosclerosis progression in healthy postmenopausal women.</p></div>","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages 752-775"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00096-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24112447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of vital status at the end of the DIG trial","authors":"Joseph F Collins Sc.D. ,&nbsp;Cindy L Howell ,&nbsp;R.Anne Horney","doi":"10.1016/j.cct.2003.08.011","DOIUrl":"10.1016/j.cct.2003.08.011","url":null,"abstract":"<div><p>The Digitalis Investigation Group (DIG) trial was a randomized, double-blind placebo-controlled trial whose primary objective was to determine whether digoxin had beneficial, harmful, or no effect on total mortality in patients with heart failure who were in sinus rhythm and whose ejection fraction was ⩽0.45. The study was designed as a large simple trial with a large number of centers (302) in the United States and Canada, many of which were inexperienced in research. To ensure that the results of the trial would be reported accurately without possible bias due to missing data, the study leadership decided that no outcome results would be reported until the vital status at the end of the study was known for at least 97% of the study participants. Planning for closeout of the study began a year prior to the common end date of December 31, 1995 and included plans for obtaining vital status on December 31, 1995. Participants were given postcards at their final study visit to be completed and mailed on or after January 1, 1996. Of 5602 postcards distributed, 5070 (90.5%) were completed and returned. A contract search agency was hired to locate the remaining participants. Of the total 7788 participants entered into the DIG trial, only 97 participants (1.2%) could not have their vital status as of December 31, 1995 determined. It is recommended that investigators having an outcome measure with a common end date include plans in their protocols for obtaining their measures and activate those plans as early as possible during the course of the study.</p></div>","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages 726-730"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cct.2003.08.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24113705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of regional coordinating centers in large clinical trials: the DIG trial","authors":"Joseph F. Collins Sc.D. ,&nbsp;Sylvia Martin R.N. ,&nbsp;Eleanor Kent R.N. ,&nbsp;Connie Liuni R.N. ,&nbsp;Rekha Garg M.D., M.S. ,&nbsp;Debra Egan M.Sc., M.P.H. ,&nbsp;on behalf of the DIG Investigators","doi":"10.1016/S0197-2456(03)00101-6","DOIUrl":"10.1016/S0197-2456(03)00101-6","url":null,"abstract":"<div><p>The Digitalis Investigation Group (DIG) trial was a large simple clinical trial that involved 302 participating centers in the United States and Canada. In order to encourage participation by Canadian investigators, to provide additional help to what were expected to be largely research-inexperienced investigators in Canada, and to provide the study's data coordinating center with resources in Canada to deal with potentially different rules, regulations, and cultural differences, regional coordinating centers were established in four regions of Canada: the maritime provinces, Quebec, Ontario, and western Canada. Canadian centers recruited significantly better than their U.S. counterparts and had slightly better retention and follow-up. While it is not possible to declare that the regional coordinating centers were responsible for this improvement, it is believed that these regional centers did play a role. This role included being able to identify investigators who could be expected to do well, providing one-on-one training and instruction to investigators, and being able to solve problems and implement change in the relatively fewer centers in their regions. The regional coordinating center also reduced the intensity of the workload on the data coordinating center by serving as the primary point of contact for Canadian investigators. The use of regional coordinating centers in studies with a large number of participating centers is highly recommended.</p></div>","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages S298-S305"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00101-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24097039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons learned from the DIG trial","authors":"Debra Egan M.Sc., M.P.H. ,&nbsp;Nancy Geller Ph.D. ,&nbsp;Salim Yusuf M.B.B.S., F.R.C.P. ,&nbsp;Rekha Garg M.D., M.S. ,&nbsp;Joseph F. Collins Sc.D. ,&nbsp;James Mathew M.D. ,&nbsp;Edward Philbin M.D. ,&nbsp;on behalf of the DIG Investigators","doi":"10.1016/S0197-2456(03)00099-0","DOIUrl":"10.1016/S0197-2456(03)00099-0","url":null,"abstract":"<div><p>The Digitalis Investigation Group (DIG) trial was the first large simple trial conducted by the National Heart, Lung, and Blood Institute in conjunction with the Department of Veterans Affairs. A large simple trial is a major undertaking. Simplification at the sites requires careful planning and discipline. Lessons learned from the DIG trial were: (1) keep a large simple trial very simple and keep all study procedures very simple; (2) ancillary studies are important and can complement a large simple trial but require careful advanced planning; (3) anticipate special needs when shipping study drugs internationally; (4) regional coordinating centers can be very useful; (5) recruit as many capable sites as possible; (6) provide research-inexperienced sites/investigators with extra help to obtain federalwide assurance statements from the Office for Human Research Protections and institutional review board approvals; (7) adequately reimburse sites for the work completed; (8) maintain investigator enthusiasm; (9) monitor the slow performers and sites with numerous personnel changes; (10) choose an endpoint that is easy to ascertain; (11) keep the trial simple for participants; and (12) plan early for closeout and for activities between the end of the trial and publication of results.</p></div>","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages S316-S326"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00099-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24096983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controlled Clinical Trials","authors":"","doi":"10.1016/S0197-2456(03)00108-9","DOIUrl":"10.1016/S0197-2456(03)00108-9","url":null,"abstract":"","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages S267-S268"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00108-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84596034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controlled Clinical Trialsatl>","authors":"","doi":"10.1016/S0197-2456(03)00166-1","DOIUrl":"https://doi.org/10.1016/S0197-2456(03)00166-1","url":null,"abstract":"","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Page iii"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00166-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137160264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"List of Reviewers","authors":"","doi":"10.1016/j.cct.2003.10.004","DOIUrl":"https://doi.org/10.1016/j.cct.2003.10.004","url":null,"abstract":"","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages 831-832"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cct.2003.10.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137280173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controlled Clinical Trials","authors":"","doi":"10.1016/S0197-2456(03)00148-X","DOIUrl":"https://doi.org/10.1016/S0197-2456(03)00148-X","url":null,"abstract":"","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Page iii"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00148-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91753957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of the DIG trial","authors":"Joseph F Collins Sc.D. ,&nbsp;Debra Egan M.Sc., M.P.H. ,&nbsp;Salim Yusuf M.B.B.S., F.R.C.P. ,&nbsp;Rekha Garg M.D., M.S. ,&nbsp;William O Williford Ph.D. ,&nbsp;Nancy Geller Ph.D. ,&nbsp;on behalf of the DIG Investigators","doi":"10.1016/S0197-2456(03)00104-1","DOIUrl":"10.1016/S0197-2456(03)00104-1","url":null,"abstract":"<div><p>Congestive heart failure is a major public health problem in the United States, Canada, and other Western countries. The Digitalis Investigation Group (DIG) trial was a randomized, double-blind placebo-controlled trial that evaluated the effects of digoxin on all-cause mortality and on hospitalization for heart failure in patients with heart failure and left ventricular ejection fraction ≤0.45 with normal sinus rhythm. It was designed as a large simple trial. There were 6800 patients entered into the main study over a 31.5-month recruitment period at 302 participating centers in the United States and Canada. All patients were followed for a minimum of 28 months. In order for this study to succeed, many groups had to work together successfully. In this supplement, we present practical aspects of organizing and conducting a large simple trial such as DIG.</p></div>","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages S269-S276"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00104-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24097036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}